Nurix Therapeutics, Inc. Common stock (NRIX)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 357
- Market Cap
- $2.4B
About Nurix Therapeutics, Inc. Common stock
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
SentiSense also tracks daily options readings for Nurix Therapeutics, Inc. Common stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Nurix Therapeutics, Inc. Common stock stock analysis, sentiment tracking, and market intelligence on SentiSense.